US20200225220A1 - Lateral flow test strip assay for osteoporosis - Google Patents
Lateral flow test strip assay for osteoporosis Download PDFInfo
- Publication number
- US20200225220A1 US20200225220A1 US16/735,604 US202016735604A US2020225220A1 US 20200225220 A1 US20200225220 A1 US 20200225220A1 US 202016735604 A US202016735604 A US 202016735604A US 2020225220 A1 US2020225220 A1 US 2020225220A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- test strip
- capture
- lateral flow
- flow test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
- A61B5/4261—Evaluating exocrine secretion production
- A61B5/4277—Evaluating exocrine secretion production saliva secretion
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/069—Absorbents; Gels to retain a fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0825—Test strips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N2021/7756—Sensor type
- G01N2021/7759—Dipstick; Test strip
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N2021/7769—Measurement method of reaction-produced change in sensor
- G01N2021/7786—Fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Definitions
- This field of this disclosure relates generally to the assay of biological markers for bone loss.
- Bone health is regulated in a tightly coupled metabolic process between bone formation (by osteoblasts) and bone resorption (by osteoclasts). In healthy bone these processes are in balance; however, these rates may become uncoupled due to diseases affecting this regulation (Paget's disease, metastatic bone cancer), or hormonal changes, as in postmenopausal women.
- BMD bone mineral density
- the traditional approach to measuring BMD is dual energy X-ray absorption (DEXA), reported as a T-score (standard deviation from mean BMD) or Z-score (standard deviation from age-matched BMD).
- DEXA is an expensive procedure, and is not readily available for general population screening. The development of a viable screening diagnostic exam for early detection of BMD loss is a long-standing problem.
- a system for screening is the detection of biomarkers of bone formation and degradation, which can be assayed in human serum or urine via concentrations of osteocalcin (OC) and deoxypyridinoline (Dpd), respectively.
- OC osteocalcin
- Dpd deoxypyridinoline
- Various embodiments of diagnostic systems disclosed reliably identify the concentrations of these biomarkers in human saliva which provides clinicians an opportunity to improve the diagnosis and prevention of osteoporosis, as well as provide a noninvasive method for convenient population screening.
- a lateral flow test strip LFTS
- OC osteocalcin
- Dpd deoxypyridinoline
- the OC assay embodiments are based on the experimentally identified optimal markers which exhibit selectivity with very low false positives, and sensitivity relevant to clinical requirements.
- a prospective clinical study sampling of 20 patients demonstrated excellent correlation of OC in saliva with bone mineral density (BMD).
- Salivary OC and Dpd levels were validated with a standard commercial enzyme-linked immunosorbent assay (ELISA) kit against serum (OC) and urine (Dpd).
- ELISA enzyme-linked immunosorbent assay
- FIG. 1 shows a single biomarker lateral flow test strip.
- FIG. 2A shows a photograph of sample quantified lateral flow assay (LFA) test strips with measured levels of Dpd.
- FIG. 2B shows a photograph of sample quantified LFA test strips with measured levels of OC.
- FIG. 3 shows a multiplex biomarker lateral flow test strip and test strip reader apparatus.
- FIG. 4 shows a chart of clinical patient results for testing salivary OC.
- FIG. 5A shows a chart of measured salivary OC compared against measured OC from serum.
- FIG. 5B shows a chart of measured salivary Dpd compared against measured Dpd from urine.
- FIG. 6 shows a correlation computation for the embodiment measured OC against the laboratory ELISA measured OC.
- FIG. 7A shows a chart of LFTS measured OC compared with BMD levels in subjects.
- FIG. 7B shows a detailed graph comparing levels of subject BMD and measured OC from the developed embodiment LFTS.
- FIG. 8 is a chart of tested and identified optimal combinations of reagents for detecting biomarkers.
- FIG. 9 is a chart of identified biomarkers suitable for various embodiments of the disclosed LFTS platform.
- the disclosed LFTS platform is a rapid immunochromatographic assay comprised of a test strip with several membranes that house all the reagents necessary for the test.
- the analyte of interest is applied in the sample medium (OC or Dpd in saliva), wherein it is captured in the test in a sandwich-antibody immunocomplex coupled to fluorescent detection.
- Monoclonal antibodies specific for OC or Dpd are conjugated to fluorescently labeled microparticles and deposited on the conjugate pad.
- the saliva Upon adding the sample to the sample pad, the saliva resolubilizes the dried antibody conjugates and forms an analyte-antibody conjugate complex, which is captured by another monoclonal antibody specific for OC or Dpd immobilized to the nitrocellulose membrane. Excitation of captured fluorescent particles generates signal response proportional to the concentration of reagent in the sample.
- FIG. 1 Shown in FIG. 1 is an exemplar LFTS 101 for a single biomarker configuration.
- the LFTS platform includes sample pad 102 , conjugate pad 103 , nitrocellulose membrane 104 and wicking pad 110 .
- Detector antibodies (OC or Dpd) 105 are carried on the conjugate pad and capture antibodies (OC or Dpd) 108 are carried by the capture line 106 .
- a control line 109 is also located on the nitrocellulose membrane.
- Flow of the sample 107 is mediated by a combination of capillary action through the membranous components from the sample pad 102 to the absorbent pad 110 , and by pressure from the liquid in the sample pad pushing toward the absorbent pad.
- Frozen samples were thawed, centrifuged to remove large particulates, and diluted 1 to 1 with our running buffer. Tests were performed in triplicate with each saliva sample. After adding 100 uL of sample volume to each test, the tests flowed for 10 minutes before the results were read with the ESE reader.
- FIG. 2A and FIG. 2B are exemplar samples. Shown are samples with Dpd concentrations of 30 nmol/L 201 A, 15 nmol/L 202 A, 7.5 nmol/L 203 A, 3.7 nmol/L 204 A, 1.8 nmol/L 205 A and 0 nmol/L 206 A. Formation of sandwich antibody detection with decreasing concentrations of Dpd. Fluorescence was observed under an ultra-violet (UV) light source. Shown in FIG. 2B are exemplar OC samples with intensity observed from spiking synthetic OC in saliva. Shown tests were run in cassettes. Fluorescence was observed under UV light source for the samples 0 ng/mL 201 B, 5 ng/mL 202 B, 10 ng/mL 203 B, 15 ng/mL 204 B and 30 ng/mL 205 B
- FIG. 3 Shown in FIG. 3 is the fluorescent reader apparatus 301 utilized for single and multiplex test strips. Shown in the inset is an embodiment for a multiplex LFTS 302 with multiple detection lines (multiplex) 303 and 304 and control line 305 .
- ELISA enzyme-linked immunosorbent assay
- salivary OC and Dpd concentrations are correlated with serum (OC) and urinary (Dpd) levels from the same patient using ELISA measurements. Samples are normalized by protein concentration to adjust for salivary specific gravity. The resulting high correlation confirms the reliability of salivary markers for the disclosed embodiment.
- Shown in FIG. 4 are results for patient samples categorized into three main groups—normal, osteopenic, and osteoporotic—showed high amounts of OC in normal patients, and low OC in osteopenic/osteoporotic patients.
- FIG. 8 shows a chart of tested capture and detector reagents along with those combinations which proved to be effective for the disclosed embodiment.
- OC reagents were screened from Fitzgerald, Novus Biologicals, Thermo Scientific, and Hytest that includes mouse anti-OC monoclonal and rabbit polyclonal antibodies for sandwich pairing and antigen testing.
- the following pairs were the only combinations that bound synthetic osteocalcin as membrane/detector: 940/939, 11F8/939, 2H9/939, 940/H10, 2H9/H10, 940/3G8, 11F8/3G8, 2H9/3G8.
- Salivary OC and Dpd concentrations were correlated with serum (OC) and urinary (Dpd) levels from the same patient using ELISA measurements. Samples were normalized by protein concentration to adjust for salivary specific gravity. The resulting high correlation suggested the reliability of salivary markers. Shown in FIG. 5A are results for salivary experimental measurements vs. the serum OC validation marker. Shown in FIG. 5B are results for salivary experimental measurements vs. the urine Dpd validation marker.
- FIG. 6 shows the correlation of OC measurements.
- the disclosed quantifiable LFTS may contain multiplexed biomarkers for both OC and Dpd.
- the LFTS shown in FIG. 3 illustrates a multiplexed LFA.
- additional biomarkers are utilized in the disclosed LFTS in either the disclosed single or multiplexed quantifiable methodology.
- Bone turnover biomarkers are represented in compounds such as collagen precursors, enzymes, and by-products, or degradation products involved with the bone formation (osteoblast) and bone resorption (osteoclast) processes.
- osteoblast bone formation
- osteoclast bone resorption
- one or more of these biomarkers are utilized in the disclosed LFTS for optimal or additional accuracy for screening examination.
- FIG. 9 provides a chart of the biomarkers identified for use in these embodiments.
- the disclosed sensitive lateral flow assay-based technique are capable of the detecting bone formation marker osteocalcin in saliva at clinically relevant levels which has been demonstrated and correlated to BMD, utilizing the disclosed readout system which as disclosed is easily integrated in a single platform for point-of-care (POC) applications.
- POC point-of-care
Abstract
Description
- This application for patent claims the benefit of and is a continuation of U.S. non-provisional patent application Ser. No. 15/078,519, filed on Mar. 23, 2016 and claims the benefit of provisional application 62/136,929 filed on Mar. 23, 2015. Both applications are incorporated herein in their entirety.
- This invention was made with government support under contract #41R43DE022478-01 awarded by the National Institute of Health. The government has certain rights in the invention.
- This field of this disclosure relates generally to the assay of biological markers for bone loss.
- Bone health is regulated in a tightly coupled metabolic process between bone formation (by osteoblasts) and bone resorption (by osteoclasts). In healthy bone these processes are in balance; however, these rates may become uncoupled due to diseases affecting this regulation (Paget's disease, metastatic bone cancer), or hormonal changes, as in postmenopausal women. When bone resorption occurs more than bone formation, a net loss in bone mineral density (BMD) results, which can lead to diseases such as osteoporosis. The traditional approach to measuring BMD is dual energy X-ray absorption (DEXA), reported as a T-score (standard deviation from mean BMD) or Z-score (standard deviation from age-matched BMD). However, DEXA is an expensive procedure, and is not readily available for general population screening. The development of a viable screening diagnostic exam for early detection of BMD loss is a long-standing problem.
- Disclosed is a system for screening is the detection of biomarkers of bone formation and degradation, which can be assayed in human serum or urine via concentrations of osteocalcin (OC) and deoxypyridinoline (Dpd), respectively. Various embodiments of diagnostic systems disclosed reliably identify the concentrations of these biomarkers in human saliva which provides clinicians an opportunity to improve the diagnosis and prevention of osteoporosis, as well as provide a noninvasive method for convenient population screening.
- Disclosed are embodiments of a lateral flow test strip (LFTS) platform which measure osteocalcin (OC) and deoxypyridinoline (Dpd) in saliva to identify early indications of bone loss and minimize bone fracture risk associated with osteoporosis. The OC assay embodiments are based on the experimentally identified optimal markers which exhibit selectivity with very low false positives, and sensitivity relevant to clinical requirements. A prospective clinical study sampling of 20 patients demonstrated excellent correlation of OC in saliva with bone mineral density (BMD). Salivary OC and Dpd levels were validated with a standard commercial enzyme-linked immunosorbent assay (ELISA) kit against serum (OC) and urine (Dpd).
-
FIG. 1 shows a single biomarker lateral flow test strip. -
FIG. 2A shows a photograph of sample quantified lateral flow assay (LFA) test strips with measured levels of Dpd. -
FIG. 2B shows a photograph of sample quantified LFA test strips with measured levels of OC. -
FIG. 3 shows a multiplex biomarker lateral flow test strip and test strip reader apparatus. -
FIG. 4 shows a chart of clinical patient results for testing salivary OC. -
FIG. 5A shows a chart of measured salivary OC compared against measured OC from serum. -
FIG. 5B shows a chart of measured salivary Dpd compared against measured Dpd from urine. -
FIG. 6 shows a correlation computation for the embodiment measured OC against the laboratory ELISA measured OC. -
FIG. 7A shows a chart of LFTS measured OC compared with BMD levels in subjects. -
FIG. 7B shows a detailed graph comparing levels of subject BMD and measured OC from the developed embodiment LFTS. -
FIG. 8 is a chart of tested and identified optimal combinations of reagents for detecting biomarkers. -
FIG. 9 is a chart of identified biomarkers suitable for various embodiments of the disclosed LFTS platform. - The disclosed LFTS platform is a rapid immunochromatographic assay comprised of a test strip with several membranes that house all the reagents necessary for the test. The analyte of interest is applied in the sample medium (OC or Dpd in saliva), wherein it is captured in the test in a sandwich-antibody immunocomplex coupled to fluorescent detection. Monoclonal antibodies specific for OC or Dpd are conjugated to fluorescently labeled microparticles and deposited on the conjugate pad. Upon adding the sample to the sample pad, the saliva resolubilizes the dried antibody conjugates and forms an analyte-antibody conjugate complex, which is captured by another monoclonal antibody specific for OC or Dpd immobilized to the nitrocellulose membrane. Excitation of captured fluorescent particles generates signal response proportional to the concentration of reagent in the sample.
- Shown in
FIG. 1 is an exemplar LFTS 101 for a single biomarker configuration. The LFTS platform includessample pad 102,conjugate pad 103,nitrocellulose membrane 104 andwicking pad 110. Detector antibodies (OC or Dpd) 105 are carried on the conjugate pad and capture antibodies (OC or Dpd) 108 are carried by thecapture line 106. Acontrol line 109 is also located on the nitrocellulose membrane. Flow of thesample 107 is mediated by a combination of capillary action through the membranous components from thesample pad 102 to theabsorbent pad 110, and by pressure from the liquid in the sample pad pushing toward the absorbent pad. - Experimental results for determining optimal configuration of the LFTS system were conducted by the following procedure. Separate, finalized test strips for OC and Dpd were placed in plastic cassettes for testing. The cassettes have an open window to view the test results, and a sample port where the sample is applied. In this embodiment the widely-used Qiagen ESE test strip fluorescent reader was adapted and calibrated with customized optical settings of emission and excitation wavelengths to read the selected fluorescent label. Other readout devices can be used for the reported platform measurements; such as LRE/SOFIA by Quidel, Cell-phone readout by Holomics, and RDS-1500 PRO by Detekt Biomedical. Saliva samples from 20 donor patients were obtained. Collected saliva samples were kept frozen at −80° C. until tested. Frozen samples were thawed, centrifuged to remove large particulates, and diluted 1 to 1 with our running buffer. Tests were performed in triplicate with each saliva sample. After adding 100 uL of sample volume to each test, the tests flowed for 10 minutes before the results were read with the ESE reader.
- Shown in
FIG. 2A andFIG. 2B are exemplar samples. Shown are samples with Dpd concentrations of 30 nmol/L L 202A, 7.5 nmol/L 203A, 3.7 nmol/L 204A, 1.8 nmol/L L 206A. Formation of sandwich antibody detection with decreasing concentrations of Dpd. Fluorescence was observed under an ultra-violet (UV) light source. Shown inFIG. 2B are exemplar OC samples with intensity observed from spiking synthetic OC in saliva. Shown tests were run in cassettes. Fluorescence was observed under UV light source for thesamples 0 ng/mL 201B, 5 ng/mL mL mL mL 205B - Shown in
FIG. 3 is thefluorescent reader apparatus 301 utilized for single and multiplex test strips. Shown in the inset is an embodiment for amultiplex LFTS 302 with multiple detection lines (multiplex) 303 and 304 andcontrol line 305. - A standard commercial enzyme-linked immunosorbent assay (ELISA) test kit was used to validate the embodiment LFTS platform with patient saliva samples. A correlation value of 0.85 was obtained with OC.
- In various embodiments salivary OC and Dpd concentrations are correlated with serum (OC) and urinary (Dpd) levels from the same patient using ELISA measurements. Samples are normalized by protein concentration to adjust for salivary specific gravity. The resulting high correlation confirms the reliability of salivary markers for the disclosed embodiment.
- Shown in
FIG. 4 are results for patient samples categorized into three main groups—normal, osteopenic, and osteoporotic—showed high amounts of OC in normal patients, and low OC in osteopenic/osteoporotic patients. - Note that for purposes of testing various embodiments, after adding 100 uL of sample volume to each test, the tests flowed for 10 minutes before the results were read with the ESE reader.
- To determine the optimum LFA components, incremental assay optimization steps were carried out for both OC and DPD assays, including capture antibody concentration, assay running buffers, purification of the antibody reagents, addition of surfactants, selection of LFA membranes, conjugate pad selection, and fabrication/drying protocols.
-
FIG. 8 shows a chart of tested capture and detector reagents along with those combinations which proved to be effective for the disclosed embodiment. To identify the antibody pair with the best affinity to osteocalcin (OC), OC reagents were screened from Fitzgerald, Novus Biologicals, Thermo Scientific, and Hytest that includes mouse anti-OC monoclonal and rabbit polyclonal antibodies for sandwich pairing and antigen testing. The following pairs were the only combinations that bound synthetic osteocalcin as membrane/detector: 940/939, 11F8/939, 2H9/939, 940/H10, 2H9/H10, 940/3G8, 11F8/3G8, 2H9/3G8. Two pairs bound strongly with native osteocalcin as membrane/detector: 940/H10, and 2H9/H10, and were used for further assay optimization and testing. Mouse monoclonal antibodies against DPD were acquired from Quidel and screened along with an antibody from a human DPD ELISA kit (MyBioSource). - Salivary OC and Dpd concentrations were correlated with serum (OC) and urinary (Dpd) levels from the same patient using ELISA measurements. Samples were normalized by protein concentration to adjust for salivary specific gravity. The resulting high correlation suggested the reliability of salivary markers. Shown in
FIG. 5A are results for salivary experimental measurements vs. the serum OC validation marker. Shown inFIG. 5B are results for salivary experimental measurements vs. the urine Dpd validation marker. - A standard commercial ELISA test kit was used to validate the disclosed LFTS platform with patient saliva samples. A correlation value of 0.85 was obtained with OC.
FIG. 6 shows the correlation of OC measurements. - In various embodiments, the disclosed quantifiable LFTS may contain multiplexed biomarkers for both OC and Dpd. The LFTS shown in
FIG. 3 illustrates a multiplexed LFA. - In various embodiments, additional biomarkers are utilized in the disclosed LFTS in either the disclosed single or multiplexed quantifiable methodology. Bone turnover biomarkers are represented in compounds such as collagen precursors, enzymes, and by-products, or degradation products involved with the bone formation (osteoblast) and bone resorption (osteoclast) processes. In various embodiments, one or more of these biomarkers are utilized in the disclosed LFTS for optimal or additional accuracy for screening examination.
FIG. 9 provides a chart of the biomarkers identified for use in these embodiments. - The disclosed sensitive lateral flow assay-based technique are capable of the detecting bone formation marker osteocalcin in saliva at clinically relevant levels which has been demonstrated and correlated to BMD, utilizing the disclosed readout system which as disclosed is easily integrated in a single platform for point-of-care (POC) applications.
- Other embodiments of the invention utilize equivalent monoclonal antibody capture and detector reagents and reagent pairs for the assay.
- What has been described herein is considered merely illustrative of the principles of this invention. Accordingly, it is well within the purview of one skilled in the art to provide other and different embodiments within the spirit and scope of the invention.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/735,604 US20200225220A1 (en) | 2015-03-23 | 2020-01-06 | Lateral flow test strip assay for osteoporosis |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562136929P | 2015-03-23 | 2015-03-23 | |
US15/078,519 US10557857B1 (en) | 2015-03-23 | 2016-03-23 | System and method for bone loss assay |
US16/735,604 US20200225220A1 (en) | 2015-03-23 | 2020-01-06 | Lateral flow test strip assay for osteoporosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/078,519 Continuation US10557857B1 (en) | 2015-03-23 | 2016-03-23 | System and method for bone loss assay |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200225220A1 true US20200225220A1 (en) | 2020-07-16 |
Family
ID=69410722
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/078,519 Active 2037-11-08 US10557857B1 (en) | 2015-03-23 | 2016-03-23 | System and method for bone loss assay |
US16/735,604 Abandoned US20200225220A1 (en) | 2015-03-23 | 2020-01-06 | Lateral flow test strip assay for osteoporosis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/078,519 Active 2037-11-08 US10557857B1 (en) | 2015-03-23 | 2016-03-23 | System and method for bone loss assay |
Country Status (1)
Country | Link |
---|---|
US (2) | US10557857B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023059921A3 (en) * | 2021-10-07 | 2023-05-19 | Intelligent Optical Systems, Inc. | Enhanced lateral flow assays and devices for detecting analytes in blood samples |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082018A1 (en) * | 2002-10-29 | 2004-04-29 | Athersys, Inc. | Methods for using osteocalcin |
US20060263825A1 (en) * | 2003-04-01 | 2006-11-23 | Proactive Oral Solutions, Inc. | Caries risk test for predicting and assessing the risk of disease |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703017C1 (en) | 1984-02-14 | 2001-12-04 | Becton Dickinson Co | Solid phase assay with visual readout |
JPH0663973B2 (en) | 1985-08-07 | 1994-08-22 | 東ソー株式会社 | Fluorescence detector used for immunoreaction measurement |
AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
US5506111A (en) | 1989-02-10 | 1996-04-09 | Teijin Limited | Method of immunological assaying of human osteocalcin, reagent and kit therefor, antibody to human osteocalcin, hybridoma producing said antibody, and method of producing it |
WO1990009587A1 (en) | 1989-02-10 | 1990-08-23 | Teijin Limited | Immunoassay of human osteocalcin, reagent and kit therefor, antihuman osteocalcin antibody, hybridoma producing said antibody, and method of producing said antibody |
US5468648A (en) | 1991-05-29 | 1995-11-21 | Smithkline Diagnostics, Inc. | Interrupted-flow assay device |
US5620861A (en) | 1992-07-31 | 1997-04-15 | Metra Biosystems, Inc. | Method and kit for pyridinium crosslink assay |
AU8017594A (en) | 1993-10-29 | 1995-05-22 | Institute Of Molecular Biology, Inc. | Osteocalcin as a marker of periodontal and peri-implant disease activity |
US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US20040259167A1 (en) * | 1997-08-15 | 2004-12-23 | Jukka Hellman | Isolated osteocalcin fragments |
US6210978B1 (en) | 1998-03-02 | 2001-04-03 | Bayer Corporation | Method and device for the detection of analyte in a fluid test sample |
US6143506A (en) * | 1998-08-13 | 2000-11-07 | The Research Foundation Of State Of Ny | Diagnostic method for detection of periodontitis or peri-implantitis |
US20060253262A1 (en) * | 2005-04-27 | 2006-11-09 | Emiliem | Novel Methods and Devices for Evaluating Poisons |
JP5097557B2 (en) | 2005-12-22 | 2012-12-12 | ローム株式会社 | Immunoassay apparatus and method |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
EP2403550A2 (en) * | 2008-11-24 | 2012-01-11 | BioE LLC | Implantable compositions for repairing osteochondral defects |
GB0917054D0 (en) * | 2009-09-29 | 2009-11-11 | Cytoguide As | Agents, uses and methods |
EP3865567A1 (en) | 2010-08-26 | 2021-08-18 | Charm Sciences Inc. | Lateral flow assay analysis |
US9700485B2 (en) * | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
-
2016
- 2016-03-23 US US15/078,519 patent/US10557857B1/en active Active
-
2020
- 2020-01-06 US US16/735,604 patent/US20200225220A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082018A1 (en) * | 2002-10-29 | 2004-04-29 | Athersys, Inc. | Methods for using osteocalcin |
US20060263825A1 (en) * | 2003-04-01 | 2006-11-23 | Proactive Oral Solutions, Inc. | Caries risk test for predicting and assessing the risk of disease |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023059921A3 (en) * | 2021-10-07 | 2023-05-19 | Intelligent Optical Systems, Inc. | Enhanced lateral flow assays and devices for detecting analytes in blood samples |
Also Published As
Publication number | Publication date |
---|---|
US10557857B1 (en) | 2020-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jokerst et al. | Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels | |
JP7235735B2 (en) | New general-purpose inspection system for quantitative analysis | |
ES2550004T3 (en) | High sensitivity system and troponin analysis methods | |
KR102489679B1 (en) | Method and device for combined detection of viral and bacterial infections | |
JP2012514184A (en) | Methods for multi-analyte detection and quantification | |
RU2397178C1 (en) | Diagnostic test system in immunochip format and differential serum diagnostics of syphilis | |
CN108333374A (en) | C reactive protein, serum amyloid A protein immunochromatography quantify combined detection test paper and preparation method thereof | |
US20170336404A1 (en) | Rapid immunoassays | |
Hong et al. | Quantitative lateral-flow immunoassay for the assessment of the cartilage oligomeric matrix protein as a marker of osteoarthritis | |
US20200225220A1 (en) | Lateral flow test strip assay for osteoporosis | |
US20150285804A1 (en) | Diagnostic method for colorectal cancer | |
KR20160120675A (en) | Rapid Quantitative Diagnostic Kit | |
KR102172016B1 (en) | A method for detection of CYFRA21-1 Autoantibody-Antigen complex , CYFRA21-1 antigen and Lung Cancer diagnosis kit by using ratio of these markers | |
US11668711B2 (en) | Multiplexed diagnostic assay for iron and vitamin A deficiency and methods of use thereof | |
US20210278423A1 (en) | Ferritin analysis via lateral flow immunoassay | |
US10996228B2 (en) | Biomarkers for assessment of preeclampsia | |
US20220214365A1 (en) | Methods of Detecting Anti-folic acid Antibodies and Uses Thereof | |
Lukens et al. | Comparison of different immunoassays for the detection of antibodies against intrinsic factor and parietal cells | |
US20210318311A1 (en) | Simultaneous detection of humoral and inflammatory biomarkers | |
CN208537565U (en) | C reactive protein, serum amyloid A protein immunochromatography quantify combined detection test paper | |
CN105705948B (en) | Apparatus and method for bioanalysis | |
EP3906113A1 (en) | Capture flow assay device and methods | |
Doppler et al. | Low-entry-barrier point-of-care testing of anti-SARS-CoV-2 IgG in the population of Upper Austria from December 2020 until April 2021—a feasible surveillance strategy for post-pandemic monitoring? | |
CN114814243B (en) | Quantitative detection kit and method applied to protein antigen | |
WO2022230991A1 (en) | Method for detecting oral neoplastic lesion, test reagent, test kit and therapeutic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: OPTECH VENTURES, LLC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INTELLIGENT OPTICAL SYSTEMS, INC.;REEL/FRAME:053234/0891 Effective date: 20200621 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: INTELLIGENT OPTICAL SYSTEMS, INC., CALIFORNIA Free format text: MERGER;ASSIGNOR:OPTECH VENTURES LLC;REEL/FRAME:063608/0027 Effective date: 20210731 |